645 related articles for article (PubMed ID: 35175551)
1. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
[TBL] [Abstract][Full Text] [Related]
2. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
3. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.
Li S; Vandvik PO; Lytvyn L; Guyatt GH; Palmer SC; Rodriguez-Gutierrez R; Foroutan F; Agoritsas T; Siemieniuk RAC; Walsh M; Frere L; Tunnicliffe DJ; Nagler EV; Manja V; Åsvold BO; Jha V; Vermandere M; Gariani K; Zhao Q; Ren Y; Cartwright EJ; Gee P; Wickes A; Ferns L; Wright R; Li L; Hao Q; Mustafa RA
BMJ; 2021 May; 373():n1091. PubMed ID: 33975892
[TBL] [Abstract][Full Text] [Related]
4. Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.
Seksaria S; Dutta BJ; Kaur M; Gupta GD; Bodakhe SH; Singh A
Curr Diabetes Rev; 2024; 20(6):e090823219597. PubMed ID: 37559236
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
6. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
Anson M; Zhao SS; Austin P; Ibarburu GH; Malik RA; Alam U
Diabetologia; 2023 Oct; 66(10):1869-1881. PubMed ID: 37505282
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
[TBL] [Abstract][Full Text] [Related]
9. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.
Morton JI; Marquina C; Shaw JE; Liew D; Polkinghorne KR; Ademi Z; Magliano DJ
Diabetologia; 2023 Apr; 66(4):642-656. PubMed ID: 36404375
[TBL] [Abstract][Full Text] [Related]
10. A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes.
Selvarajan R; Subramanian R
Diabetes Metab Syndr Obes; 2023; 16():1709-1720. PubMed ID: 37312901
[TBL] [Abstract][Full Text] [Related]
11. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
12. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents.
Cornell S
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):17-27. PubMed ID: 32910490
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future.
Ferrari F; Scheffel RS; Martins VM; Santos RD; Stein R
Am J Cardiovasc Drugs; 2022 Jul; 22(4):363-383. PubMed ID: 34958423
[TBL] [Abstract][Full Text] [Related]
14. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Guyton J; Jeon M; Brooks A
Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
[TBL] [Abstract][Full Text] [Related]
17. Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care.
Orsini Federici M; Gentilella R; Corcos A; Torre E; Genovese S
Diabetes Metab Res Rev; 2021 Oct; 37(7):e3434. PubMed ID: 33900667
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 receptor agonists use for type 2 diabetes mellitus in end-stage renal disease.
Thomas AM; Lamb K; Howard O
J Am Pharm Assoc (2003); 2023; 63(5):1612-1616. PubMed ID: 37301509
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
Gilbert MP; Pratley RE
Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
[TBL] [Abstract][Full Text] [Related]
20. Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis.
Kelly M; Lewis J; Rao H; Carter J; Portillo I; Beuttler R
Pharmacotherapy; 2022 Dec; 42(12):921-928. PubMed ID: 36271706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
